Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomark Prev. 2011;20(8):1629–37.
Article
Google Scholar
Wagner AD, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C, Coukos G, Dafni U, Dotto GP, Ducreux M, et al. Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol. 2019;30(12):1914–24.
Article
CAS
PubMed
Google Scholar
Özdemir BC, Csajka C, Dotto G-P, Wagner AD. Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology. J Clin Oncol. 2018;36(26):2680–3.
Article
PubMed
Google Scholar
Van Anders SM, Schudson ZC, Abed EC, Beischel WJ, Dibble ER, Gunther OD, Kutchko VJ, Silver ER. Biological sex, gender, and public policy. Policy Insights Behav Brain Sci. 2017;4(2):194–201.
Article
Google Scholar
Group SaGSRCtA. Wainer Z, Carcel C: Sex and gender in health research: updating policy to reflect evidence. Med J Aust. 2020;212(2):57-62.e1.
Article
Google Scholar
Krieger N. Genders, sexes, and health: what are the connections–and why does it matter? Int J Epidemiol. 2003;32(4):652–7.
Article
PubMed
Google Scholar
Springer KW, Mager Stellman J, Jordan-Young RM. Beyond a catalogue of differences: a theoretical frame and good practice guidelines for researching sex/gender in human health. Soc Sci Med. 2012;74(11):1817–24.
Article
PubMed
Google Scholar
Rich-Edwards JW, Kaiser UB, Chen GL, Manson JE, Goldstein JM. Sex and gender differences research design for basic, clinical, and population studies: essentials for investigators. Endocr Rev. 2018;39(4):424–39.
Article
PubMed
PubMed Central
Google Scholar
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–38.
Article
CAS
PubMed
Google Scholar
Mirandola L, Wade R, Verma R, Pena C, Hosiriluck N, Figueroa JA, Cobos E, Jenkins MR, Chiriva-Internati M. Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium. Int Rev Immunol. 2015;34(2):134–42.
Article
CAS
PubMed
Google Scholar
Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT. Vitamin D status: United States, 2001–2006. NCHS Data Brief. 2011;59:1–8.
Google Scholar
Tolin DF, Foa EB. Sex differences in trauma and posttraumatic stress disorder: a quantitative review of 25 years of research. Psychol Bull. 2006;132(6):959–92.
Article
PubMed
Google Scholar
Breiding MJ, Smith SG, Basile KC, Walters ML, Chen J, Merrick MT. Prevalence and characteristics of sexual violence, stalking, and intimate partner violence victimization—national intimate partner and sexual violence survey, United States, 2011. MMWR Surveill Summ. 2014;63(8):1–18.
PubMed
Google Scholar
Becker JB, Arnold AP, Berkley KJ, Blaustein JD, Eckel LA, Hampson E, Herman JP, Marts S, Sadee W, Steiner M, et al. Strategies and methods for research on sex differences in brain and behavior. Endocrinology. 2005;146(4):1650–73.
Article
CAS
PubMed
Google Scholar
Agabio R, Pisanu C, Gessa GL, Franconi F. Sex differences in alcohol use disorder. Curr Med Chem. 2017;24(24):2661–70.
Article
CAS
PubMed
Google Scholar
Zhu Y, Shao X, Wang X, Liu L, Liang H. Sex disparities in cancer. Cancer Lett. 2019;466:35–8.
Article
CAS
PubMed
Google Scholar
Sun D, Li H, Cao M, He S, Lei L, Peng J, Chen W. Cancer burden in China: trends, risk factors and prevention. Cancer Biol Med. 2020;17(4):879–95.
Article
PubMed
PubMed Central
Google Scholar
Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature. 2014;509(7500):282–3.
Article
PubMed
PubMed Central
Google Scholar
Gemmati D, Varani K, Bramanti B, Piva R, Bonaccorsi G, Trentini A, Manfrinato MC, Tisato V, Carè A, Bellini T. “Bridging the Gap” Everything that Could Have Been Avoided If We Had Applied Gender Medicine, Pharmacogenetics and Personalized Medicine in the Gender-Omics and Sex-Omics Era. Int J Mol Sci. 2019;21(1):296.
Article
PubMed Central
Google Scholar
Oliva M, Munoz-Aguirre M, Kim-Hellmuth S, Wucher V, Gewirtz ADH, Cotter DJ, Parsana P, Kasela S, Balliu B, Vinuela A, et al. The impact of sex on gene expression across human tissues. Science. 2020;369(6509):eaba3066.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lopes-Ramos CM, Chen CY, Kuijjer ML, Paulson JN, Sonawane AR, Fagny M, Platig J, Glass K, Quackenbush J, DeMeo DL. Sex differences in gene expression and regulatory networks across 29 human tissues. Cell Rep. 2020;31(12): 107795.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kwon H, Schafer JM, Song N-J, Kaneko S, Li A, Xiao T, Ma A, Allen C, Das K, Zhou L, et al. Androgen conspires with the CD8 T cell exhaustion program and contributes to sex bias in cancer. Sci Immunol. 2022;7(73):eabq2630.
Article
CAS
PubMed
PubMed Central
Google Scholar
Clocchiatti A, Cora E, Zhang Y, Dotto GP. Sexual dimorphism in cancer. Nat Rev Cancer. 2016;16(5):330–9.
Article
CAS
PubMed
Google Scholar
Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86.
Article
PubMed
Google Scholar
Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):737–46.
Article
CAS
PubMed
Google Scholar
Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, Pagan E, Pennacchioli E, Cocorocchio E, Ferrucci PF, De Marinis F, et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J Natl Cancer Inst. 2019;111(8):772–81.
Article
PubMed
PubMed Central
Google Scholar
Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis. JAMA Oncol. 2019;5(4):529–36.
Article
PubMed
PubMed Central
Google Scholar
Wu Y, Ju Q, Jia K, Yu J, Shi H, Wu H, Jiang M. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). Int J Cancer. 2018;143(1):45–51.
Article
CAS
PubMed
Google Scholar
Grassadonia A, Sperduti I, Vici P, Iezzi L, Brocco D, Gamucci T, Pizzuti L, Maugeri-Saccà M, Marchetti P, Cognetti G, et al. Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. J Clin Med. 2018;7(12):542.
Article
PubMed Central
Google Scholar
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D’Haese JG, Schloesser H, et al. Advances in cancer immunotherapy 2019—latest trends. J Exp Clin Cancer Res. 2019;38(1):268.
Article
PubMed
PubMed Central
Google Scholar
Castro A, Pyke RM, Zhang X, Thompson WK, Day CP, Alexandrov LB, Zanetti M, Carter H. Strength of immune selection in tumors varies with sex and age. Nat Commun. 2020;11(1):4128.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TDL, Levesque M, Dummer R, et al. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017;116(9):1141–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin Cancer Res. 2018;24(21):5347–56.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu H, Han L. Sex-associated molecular differences for cancer immunotherapy. Nat Commun. 2020;11(1):1779.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang S, Cowley LA, Liu XS. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. Molecules. 2019;24(18):3214.
Article
CAS
PubMed Central
Google Scholar
Haupt S, Caramia F, Klein SL, Rubin JB, Haupt Y. Sex disparities matter in cancer development and therapy. Nat Rev Cancer. 2021;21(6):393–407.
Article
CAS
PubMed
PubMed Central
Google Scholar
Massimini M, Palmieri C, De Maria R, Romanucci M, Malatesta D, De Martinis M, Maniscalco L, Ciccarelli A, Ginaldi L, Buracco P, et al. 17-AAG and apoptosis, autophagy, and mitophagy in canine osteosarcoma cell lines. Vet Pathol. 2017;54(3):405–12.
Article
CAS
PubMed
Google Scholar
Ma J, Hu X, Yao Y, Wu L, Sheng C, Chen K, Liu B. Characterization of two ferroptosis subtypes with distinct immune infiltration and gender difference in gastric cancer. Front Nutr. 2021;8: 756193.
Article
PubMed
PubMed Central
Google Scholar
Lista P, Straface E, Brunelleschi S, Franconi F, Malorni W. On the role of autophagy in human diseases: a gender perspective. J Cell Mol Med. 2011;15(7):1443–57.
Article
CAS
PubMed
PubMed Central
Google Scholar
Conforti F, Pala L, Pagan E, Bagnardi V, De Pas T, Queirolo P, Pennacchioli E, Catania C, Cocorocchio E, Ferrucci PF, et al. Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion. Clin Cancer Res. 2021;27(15):4311–24.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gupta S, Nakabo S, Blanco LP, O’Neil LJ, Wigerblad G, Goel RR, Mistry P, Jiang K, Carmona-Rivera C, Chan DW, et al. Sex differences in neutrophil biology modulate response to type I interferons and immunometabolism. Proc Natl Acad Sci U S A. 2020;117(28):16481–91.
Article
CAS
PubMed
PubMed Central
Google Scholar
Credendino SC, Neumayer C, Cantone I. Genetics and epigenetics of sex bias: insights from human cancer and autoimmunity. Trends Genet. 2020;36(9):650–63.
Article
CAS
PubMed
Google Scholar
Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N, Subtypes PT, Clinical T, Boutros PC, Consortium P. Sex differences in oncogenic mutational processes. Nat Commun. 2020;11(1):4330.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li CH, Haider S, Shiah Y-J, Thai K, Boutros PC. Sex differences in cancer driver genes and biomarkers. Cancer Res. 2018;78(19):5527–37.
Article
CAS
PubMed
Google Scholar
Gupta S, Artomov M, Goggins W, Daly M, Tsao H. Gender Disparity and Mutation Burden in Metastatic Melanoma. J Natl Cancer Inst. 2015;107(11):djv221.
Article
PubMed
PubMed Central
Google Scholar
Podolskiy DI, Lobanov AV, Kryukov GV, Gladyshev VN. Analysis of cancer genomes reveals basic features of human aging and its role in cancer development. Nat Commun. 2016;7:12157.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.
Article
Google Scholar
Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, Fassan M, Rugge M, Valeri N, Okines A, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3(9):1197–203.
Article
PubMed
Google Scholar
Matthews B, Waxman DJb. CTCF and Cohesin link sex-biased distal regulatory elements to sex-biased gene expression in mouse liver. bioRxiv. (2019):577577.
Matthews BJ, Waxman DJ. Impact of 3D genome organization, guided by cohesin and CTCF looping, on sex-biased chromatin interactions and gene expression in mouse liver. Epigenet Chrom. 2020;13(1):30.
Article
CAS
Google Scholar
Liu EM, Martinez-Fundichely A, Diaz BJ, Aronson B, Cuykendall T, MacKay M, Dhingra P, Wong EWP, Chi P, Apostolou E, et al. Identification of Cancer Drivers at CTCF Insulators in 1,962 Whole Genomes. Cell Syst. 2019;8(5):446–55.e8.
Balaton BP, Brown CJ. Escape artists of the X chromosome. Trends Genet. 2016;32(6):348–59.
Article
CAS
PubMed
Google Scholar
Aken BL, Ayling S, Barrell D, Clarke L, Curwen V, Fairley S, Fernandez Banet J, Billis K, García Girón C, Hourlier T, et al. The Ensembl gene annotation system. Database (Oxford). 2016;2016:baw093.
Article
PubMed
PubMed Central
Google Scholar
Cáceres A, Jene A, Esko T, Pérez-Jurado LA, González JR. Extreme downregulation of chromosome Y and cancer risk in men. J Natl Cancer Inst. 2020;112(9):913–20.
Article
PubMed
PubMed Central
Google Scholar
Loftfield E, Zhou W, Graubard BI, Yeager M, Chanock SJ, Freedman ND, Machiela MJ. Predictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank. Sci Rep. 2018;8(1):12316.
Article
PubMed
PubMed Central
Google Scholar
Sano S, Horitani K, Ogawa H, Halvardson J, Chavkin NW, Wang Y, Sano M, Mattisson J, Hata A, Danielsson M, et al. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. Science (New York, NY). 2022;377(6603):292–7.
Article
CAS
Google Scholar
Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12(1):76.
Article
PubMed
PubMed Central
Google Scholar
Brown JM, Recht L, Strober S. The promise of targeting macrophages in cancer therapy. Clin Cancer Res. 2017;23(13):3241–50.
Article
PubMed
PubMed Central
Google Scholar
Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, Li J, Mills Gordon B, Shu Y, Li L, et al. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell. 2016;29(5):711–22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sarne V, Huter S, Braunmueller S, Rakob L, Jacobi N, Kitzwögerer M, Wiesner C, Obrist P, Seeboeck R. Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines. Int J Mol Sci. 2020;21(13):4595.
Article
CAS
PubMed Central
Google Scholar
Li L, Liu X, Sanders KL, Edwards JL, Ye J, Si F, Gao A, Huang L, Hsueh EC, Ford DA, et al. TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy. Cell Metab. 2019;29(1):103-123.e5.
Article
CAS
PubMed
Google Scholar
Ono M. Control of regulatory T-cell differentiation and function by T-cell receptor signalling and Foxp3 transcription factor complexes. Immunology. 2020;160(1):24–37.
Article
CAS
PubMed
PubMed Central
Google Scholar
Huang L, Xu H, Peng G. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy. Cell Mol Immunol. 2018;15(5):428–37.
Article
CAS
PubMed
PubMed Central
Google Scholar
Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE, Aderem A. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci U S A. 2005;102(27):9577–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Souyris M, Cenac C, Azar P, Daviaud D, Canivet A, Grunenwald S, Pienkowski C, Chaumeil J, Mejía JE, Guéry J-C. TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol. 2018;3(19):eaap8855.
Article
PubMed
Google Scholar
Golden LC, Itoh Y, Itoh N, Iyengar S, Coit P, Salama Y, Arnold AP, Sawalha AH, Voskuhl RR. Parent-of-origin differences in DNA methylation of X chromosome genes in T lymphocytes. Proc Natl Acad Sci U S A. 2019;116(52):26779–87.
Article
CAS
PubMed Central
Google Scholar
Márquez EJ, Chung C-H, Marches R, Rossi RJ, Nehar-Belaid D, Eroglu A, Mellert DJ, Kuchel GA, Banchereau J, Ucar D. Sexual-dimorphism in human immune system aging. Nat Commun. 2020;11(1):751.
Article
PubMed
PubMed Central
Google Scholar
Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89–102.
Article
CAS
PubMed
Google Scholar
Delbridge ARD, Kueh AJ, Ke F, Zamudio NM, El-Saafin F, Jansz N, Wang G-Y, Iminitoff M, Beck T, Haupt S, et al. Loss of p53 Causes Stochastic Aberrant X-Chromosome Inactivation and Female-Specific Neural Tube Defects. Cell Rep. 2019;27(2):442-454.e5.
Article
CAS
PubMed
Google Scholar
Menendez D, Snipe J, Marzec J, Innes CL, Polack FP, Caballero MT, Schurman SH, Kleeberger SR, Resnick MA. p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus. J Clin Invest. 2019;129(11):4875–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Müller O, Back W, Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998;18(1):38–43.
Article
CAS
PubMed
Google Scholar
Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cheng F, Jia P, Wang Q, Lin CC, Li WH, Zhao Z. Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. Mol Biol Evol. 2014;31(8):2156–69.
Article
CAS
PubMed
PubMed Central
Google Scholar
Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, et al. Mutations and PD-1 inhibitor resistance in -mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822–35.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, Zhang J, Tolstorukov MY, Li YY, Spurr LF, et al. Diminished efficacy of programmed death-(Ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J Thorac Oncol. 2022;17(3):399–410.
Article
CAS
PubMed
Google Scholar
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.
Article
CAS
PubMed
PubMed Central
Google Scholar
Irelli A, Sirufo MM, D’Ugo C, Ginaldi L, De Martinis M. Sex and Gender Influences on Cancer Immunotherapy Response. Biomedicines. 2020;8(7):232.
Article
CAS
PubMed Central
Google Scholar
Matsumoto T, Sakari M, Okada M, Yokoyama A, Takahashi S, Kouzmenko A, Kato S. The androgen receptor in health and disease. Annu Rev Physiol. 2013;75:201–24.
Article
CAS
PubMed
Google Scholar
Nugent BM, Wright CL, Shetty AC, Hodes GE, Lenz KM, Mahurkar A, Russo SJ, Devine SE, McCarthy MM. Corrigendum: brain feminization requires active repression of masculinization via DNA methylation. Nat Neurosci. 2017;20(6):896.
Article
CAS
PubMed
Google Scholar
Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, Ho A, Mei PH, et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature. 2009;462(7269):58–64.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, et al. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022;606(7915):797–803.
Article
CAS
PubMed
Google Scholar
Yang C, Jin J, Yang Y, Sun H, Wu L, Shen M, Hong X, Li W, Lu L, Cao D, et al. Androgen receptormediated CD8 T cell stemness programs drive sex differences in antitumor immunity. Immunity. 2022;55(7):1268-1283.e9.
Article
CAS
PubMed
Google Scholar
Clocchiatti A, Ghosh S, Procopio M-G, Mazzeo L, Bordignon P, Ostano P, Goruppi S, Bottoni G, Katarkar A, Levesque M, et al. Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. J Clin Invest. 2018;128(12):5531–48.
Article
PubMed
PubMed Central
Google Scholar
Liu B, Zhou M, Li X, Zhang X, Wang Q, Liu L, Yang M, Yang D, Guo Y, Zhang Q, et al. Interrogation of gender disparity uncovers androgen receptor as the transcriptional activator for oncogenic miR-125b in gastric cancer. Cell Death Dis. 2021;12(5):441.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhao R, Chen X, Ma W, Zhang J, Guo J, Zhong X, Yao J, Sun J, Rubinfien J, Zhou X, et al. A GPR174-CCL21 module imparts sexual dimorphism to humoral immunity. Nature. 2020;577(7790):416–20.
Article
CAS
PubMed
Google Scholar
Guan X, Polesso F, Wang C, Sehrawat A, Hawkins RM, Murray SE, Thomas GV, Caruso B, Thompson RF, Wood MA, et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature. 2022;606(7915):791–6.
Article
CAS
PubMed
Google Scholar
Kiyotani K, Toyoshima Y, Nakamura Y. Personalized immunotherapy in cancer precision medicine. Cancer Biol Med. 2021;18(4):955–65.
CAS
PubMed Central
Google Scholar
Lotz M, Budden T, Furney SJ, Virós A. Molecular subtype, biological sex and age shape melanoma tumour evolution. Br J Dermatol. 2021;184(2):328–37.
Article
CAS
PubMed
Google Scholar
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99.
Article
PubMed
PubMed Central
Google Scholar
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bosse D, Wankowicz SM, Cullen D, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56.
Article
CAS
PubMed
Google Scholar
Wang S, Zhang J, He Z, Wu K, Liu XS. The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex. Int J Cancer. 2019;145(10):2840–9.
Article
CAS
PubMed
Google Scholar
Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med. 2018;10(1):93.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fusi A, Festino L, Botti G, Masucci G, Melero I, Lorigan P, Ascierto PA. PD-L1 expression as a potential predictive biomarker. Lancet Oncol. 2015;16(13):1285–7.
Article
PubMed
Google Scholar
Lorbeer FK, Hockemeyer D. TERT promoter mutations and telomeres during tumorigenesis. Curr Opin Genet Dev. 2020;60:56–62.
Article
CAS
PubMed
Google Scholar
Osella-Abate S, Bertero L, Senetta R, Mariani S, Lisa F, Coppola V, Metovic J, Pasini B, Puig SS, Fierro MT, et al. TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk. Cancers (Basel). 2019;11(4):452.
Article
CAS
PubMed Central
Google Scholar
Leão R, Lee D, Figueiredo A, Hermanns T, Wild P, Komosa M, Lau I, Mistry M, Nunes NM, Price AJ, et al. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. Int J Cancer. 2019;144(7):1676–84.
Article
PubMed
Google Scholar
Li J, Li Z, Zhang C, Zhang C, Wang H. Male patients with TERT mutation may be more likely to benefit from immunotherapy, especially for melanoma. Aging (Albany NY). 2020;12(17):17288–94.
Article
CAS
Google Scholar
Ramsey JM, Cooper JD, Penninx BWJH, Bahn S. Variation in serum biomarkers with sex and female hormonal status: implications for clinical tests. Sci Rep. 2016;6:26947.
Article
CAS
PubMed
PubMed Central
Google Scholar
Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.
Article
CAS
PubMed
Google Scholar
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
Article
CAS
PubMed
Google Scholar
Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104.
Article
PubMed
Google Scholar
Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH, Calabrese L. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504–15.
Article
CAS
PubMed
Google Scholar
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suarez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.
Article
PubMed
Google Scholar
Jing Y, Zhang Y, Wang J, Li K, Chen X, Heng J, Gao Q, Ye Y, Zhang Z, Liu Y, et al. Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy. J Natl Cancer Inst. 2021;113(10):1396–404.
Article
PubMed
Google Scholar
Unger JM, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC, Henry NL, Fisch MJ, Lee SM, Blanke CD, et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol. 2022;40(13):1474–86.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu Y, Beyer A, Aebersold R. On the dependency of cellular protein levels on mRNA abundance. Cell. 2016;165(3):535–50.
Article
CAS
PubMed
Google Scholar
Allen AM, Scheuermann TS, Nollen N, Hatsukami D, Ahluwalia JS. Gender differences in smoking behavior and dependence motives among daily and nondaily smokers. Nicotine Tob Res. 2016;18(6):1408–13.
Article
PubMed
Google Scholar